Drug Profile
ORG 31550
Alternative Names: SR 80027; SR 80027ALatest Information Update: 08 Jan 2001
Price :
$50
*
At a glance
- Originator Organon; Sanofi-Synthelabo
- Class Antithrombotics; Glycosaminoglycans; Oligosaccharides
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 08 Jan 2001 Discontinued-Preclinical for Thrombosis in France (Unknown route)
- 08 Jan 2001 Discontinued-Preclinical for Thrombosis in Netherlands (Unknown route)
- 27 Aug 1999 Sanofi has merged with Synthélabo to form Sanofi-Synthélabo